资讯

manilatimes4 个月
2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2 ...
Ltd. ("RemeGen") (9995.HK, 688331.SH) presented for the first time the data from a phase III study (RC48-C006, NCT03500380) of Disitamab Vedotin (DV) in treating patients with HER2-positive advanced ...